Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.
Also called NCT07296484
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 1,500 participants
- Sponsor
- Sparrow Pharmaceuticals
- Registry
-
NCT07296484
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07296484. Randomized; quadruple masking; primary purpose other. Start 2025-11-29 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
- Acronym
- CAPTAIN-T2D
- Condition
- Type 2 Diabetes
- Condition
- Cortisol Excess
- Intervention (Drug)
- clofutriben
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sparrow Pharmaceuticals
Record details
- Record id
cardio:ct-nct07296484- Content hash
6b95e69d694b814baabec8b355172560e8b7917d36de94089ba3d95d7ea3a23d